# AMTEC IIT: Phase 2 Multiarm Study in TNBC

> **NCT03801369** · PHASE2 · TERMINATED · sponsor: **Gordon Mills, MD, PhD** · enrollment: 24 (actual)

## Conditions studied

- Anatomic Stage IV Breast Cancer AJCC v8
- Metastatic Triple-Negative Breast Carcinoma

## Interventions

- **PROCEDURE:** Biopsy
- **DRUG:** Capivasertib
- **DRUG:** Ceralasertib
- **BIOLOGICAL:** Durvalumab
- **DRUG:** Olaparib
- **OTHER:** Quality-of-Life Assessment
- **DRUG:** Selumetinib

## Key facts

- **NCT ID:** NCT03801369
- **Lead sponsor:** Gordon Mills, MD, PhD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-12-12
- **Primary completion:** 2024-10-22
- **Final completion:** 2024-12-23
- **Target enrollment:** 24 (ACTUAL)
- **Why stopped:** loss of funding
- **Last updated:** 2026-02-25

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03801369

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03801369, "AMTEC IIT: Phase 2 Multiarm Study in TNBC". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT03801369. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*